Prestroke Antiplatelet Effect on Symptomatic Intracranial Hemorrhage and Functional Outcome in Intravenous Thrombolysis

다국어 초록 (Multilingual Abstract)

Background and Purpose About 30%-40% of stroke patients are taking antiplatelet at the time of their strokes, which might increase the risk of symptomatic intracranial hemorrhage (SICH) with intravenous tissue plasminogen activator (IV-TPA) therapy. We aimed to assess the effect of prestroke antiplatelet on the SICH risk and functional outcome in Koreans treated with IV-TPA.
Methods From a prospective stroke registry, we identified patients treated with IV-TPA between October 2009 and November 2014. Prestroke antiplatelet use was defined as taking antiplatelet within 7 days before the stroke onset. The primary outcome was SICH. Secondary outcomes were discharge modified Rankin Scale (mRS) score and in-hospital mortality.
Results Of 1,715 patients treated with IV-TPA, 441 (25.7%) were on prestroke antiplatelet. Prestroke antiplatelet users versus non-users were more likely to be older, to have multiple vascular risk factors. Prestroke antiplatelet use was associated with an increased risk of SICH (5.9% vs. 3.0%; adjusted odds ratio [OR] 1.79 [1.05-3.04]). However, at discharge, the two groups did not differ in mRS distribution (adjusted OR 0.90 [0.72-1.14]), mRS 0-1 outcome (34.2% vs. 33.7%; adjusted OR 1.27 [0.94-1.72), mRS 0-2 outcome (52.4% vs. 52.9%; adjusted OR 1.21 [0.90-1.63]), and in-hospital mortality (6.1% vs. 4.2%; adjusted OR 1.19 [0.71-2.01]).
Conclusions Despite an increased risk of SICH, prestroke antiplatelet users compared to non-users had comparable functional outcomes and in-hospital mortality with IV-TPA therapy. Our results support the use of IV-TPA in eligible patients taking antiplatelet therapy before their stroke onset.

참고문헌 (Reference)

1 조경희, "한국 뇌졸중 진료지침 급성기 치료 중 혈전용해술에 대한 내용의 부분개정" 대한뇌졸중학회 14 (14): 95-105, 2012

2 Whiteley WN, "Targeting recombinant tissue-type plasminogen activator in acute ischemic stroke based on risk of intracranial hemorrhage or poor functional outcome : an analysis of the third international stroke trial" 45 : 1000-1006, 2014

3 Bluhmki E, "Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial" 8 : 1095-1102, 2009

4 Diedler J, "Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset" 41 : 288-294, 2010

5 Xian Y, "Risks and benefits associated with prestroke antiplatelet therapy among patients with acute ischemic stroke treated with intravenous tissue plasminogen activator" 73 : 50-59, 2016

6 Larrue V, "Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator : a secondary analysis of the European-Australasian Acute Stroke Study(ECASS II)" 32 : 438-441, 2001

7 Whiteley WN, "Risk factors for intracranial hemorrhage in acute ischemic stroke patients treated with recombinant tissue plasminogen activator : a systematic review and meta-analysis of 55 studies" 43 : 2904-2909, 2012

8 Mehta RH, "Race/Ethnic differences in the risk of hemorrhagic complications among patients with ischemic stroke receiving thrombolytic therapy" 45 : 2263-2269, 2014

9 Pan X, "Prior antiplatelet agent use and outcomes after intravenous thrombolysis with recombinant tissue plasminogen activator in acute ischemic stroke : a meta-analysis of cohort studies and randomized controlled trials" 10 : 317-323, 2015

10 Pan Y, "Preexisting dual antiplatelet treatment increases the risk of post-thrombolysis intracranial hemorrhage in Chinese stroke patients" 37 : 64-68, 2015

11 Mazya M, "Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase : safe Implementation of Treatments in Stroke(SITS)symptomatic intracerebral hemorrhage risk score" 43 : 1524-1531, 2012

12 Chao AC, "Outcomes of thrombolytic therapy for acute ischemic stroke in Chinese patients : the Taiwan Thrombolytic Therapy for Acute Ischemic Stroke(TTT-AIS)study" 41 : 885-890, 2010

13 Wahlgren N, "Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials : Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy(SITS-MOST)" 39 : 3316-3322, 2008

14 Tanne D, "Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice : the Multicenter rt-PA Stroke Survey" 105 : 1679-1685, 2002

15 Cucchiara B, "Factors associated with intracerebral hemorrhage after thrombolytic therapy for ischemic stroke : pooled analysis of placebo data from the Stroke-Acute Ischemic NXY Treatment(SAINT)I and SAINT II Trials" 40 : 3067-3072, 2009

16 Ibrahim MM, "Does current oral antiplatelet agent or subtherapeutic anticoagulation use have an effect on tissue-plasminogen-activator-mediated recanalization rate in patients with acute ischemic stroke?" 30 : 508-513, 2010

17 Kim BJ, "Current status of acute stroke management in Korea: a report on a multicenter, comprehensive acute stroke registry" 9 : 514-518, 2014

18 Ciolino JD, "Covariate imbalance and adjustment for logistic regression analysis of clinical trial data" 23 : 1383-1402, 2013

19 김범준, "Case Characteristics, Hyperacute Treatment, and Outcome Information from the Clinical Research Center for Stroke-Fifth Division Registry in South Korea" 대한뇌졸중학회 17 (17): 38-53, 2015

20 Hallevi H, "Antiplatelet therapy and the risk of intracranial hemorrhage after intravenous tissue plasminogen activator therapy for acute ischemic stroke" 65 : 575-576, 2008